All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
PERTH, Australia – Mesoblast Ltd. plans to evaluate remestemcel-L in patients with acute respiratory distress syndrome caused by coronavirus (COVID-19) in the U.S., Australia, China and Europe.
